{"entity":{"id":"nct07254585","kind":"trial","name":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of SYS6010 in head and neck squamous cell carcinoma, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","summary":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07254585 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 70 participants planned, started 2025-12-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: SYS6010 injection, Enlonstobart injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07254585","url":"https://clinicaltrials.gov/study/NCT07254585"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["sys6010"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07254585","phase":"2","setting":"An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Enlonstobart in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":70,"outcomes":[]},"route":"/trials/nct07254585/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}